Radiation‐Free Haploidentical Transplantation With PTCy and Extended Abatacept in Pediatric Nonmalignant Disorders
Authors:
- Thomas PfeifferTPThomas Pfeiffer
- Alexander NgwubeANAlexander Ngwube
- Rachel E. GranbergRGRachel E. Granberg
- Ginny SchulzGSGinny Schulz
- Allison A. KingAKAllison A. King
- Melissa MaversMMMelissa Mavers
- Robert J. HayashiRHRobert J. Hayashi
- Jeffrey J. BednarskiJBJeffrey J. Bednarski
- Emi CaywoodECEmi Caywood
- Troy C. QuiggTQTroy C. Quigg
Open Access
- 1 October 2026
- journal article
- other
- Published by Wiley in American Journal of Hematology
- Vol. 101 (12) , 3082-3086
Abstract
No abstract availableKeywords
This publication has 15 references indexed in Scilit:
- Impact of Abatacept Inclusive Graft-Versus-Host Disease Prophylaxis in Pediatric Stem Cell Transplantation for HemoglobinopathyTransplantation and Cellular Therapy, 2025
- Abatacept for acute graft-versus-host disease prophylaxis after unrelated donor hematopoietic cell transplantationBlood, 2024
- An international learning collaborative phase 2 trial for haploidentical bone marrow transplant in sickle cell diseaseBlood, 2024
- Long-Term Follow-Up of Abatacept, Post-Transplantation Cyclophosphamide, and Sirolimus-Based Haploidentical Transplantation in Younger Patients with Nonmalignant DiseasesTransplantation and Cellular Therapy, 2024
- The effect of abatacept on T-cell activation is not long-lived in vivoDiscovery Immunology, 2024
- Post-Transplantation Cyclophosphamide-Based Graft-versus-Host Disease ProphylaxisNew England Journal of Medicine, 2023
- Haploidentical BMT for severe aplastic anemia with intensive GVHD prophylaxis including posttransplant cyclophosphamideBlood Advances, 2020
- How we perform haploidentical stem cell transplantation with posttransplant cyclophosphamideBlood, 2019
- In Vivo T Cell Costimulation Blockade with Abatacept for Acute Graft-versus-Host Disease Prevention: A First-in-Disease TrialTransplantation and Cellular Therapy, 2013
- HLA-Haploidentical Bone Marrow Transplantation for Hematologic Malignancies Using Nonmyeloablative Conditioning and High-Dose, Posttransplantation CyclophosphamideTransplantation and Cellular Therapy, 2008